AOD 9604 peptide injection explained: how this hGH fragment works, what research says about fat loss, typical dosing, safety, and FDA status.
AOD 9604 peptide injection is a synthetic fragment of human growth hormone (hGH) that is injected subcutaneously and marketed as a fat-loss agent. It matches the C-terminal region of hGH — amino acids 176–191 — and was engineered to trigger lipolysis without the growth, blood sugar, or IGF-1 effects of full growth hormone. AOD 9604 is not FDA-approved for human use in the United States, and it is legally sold only as a research chemical.
What Is AOD 9604 Peptide?
AOD 9604 (often written AOD-9604) was developed by the Australian company Metabolic Pharmaceuticals as a candidate anti-obesity drug. Scientists trimmed the hGH molecule down to the segment believed to drive fat breakdown, then modified it to last longer in the bloodstream.
The peptide ships as a lyophilized powder that must be reconstituted with bacteriostatic water before use. Research protocols typically describe subcutaneous injections into the abdomen or thigh with an insulin-style syringe.
Because the fragment is small and short-lived, it does not appear to enter the same pathways that make full growth hormone risky at high doses. That selectivity is the main reason it still circulates in bodybuilding and anti-aging circles despite its regulatory status.
How AOD 9604 Works in the Body
AOD 9604 is believed to act partly through beta-3 adrenergic receptors, stimulating lipolysis — the release of stored fat — while inhibiting lipogenesis, the process that builds and stores new fat. Animal studies showed increased fat oxidation and reduced fat mass in obese mice without a change in food intake.
Early pharmacokinetic work measured a half-life of roughly 30 minutes, which is why once- or twice-daily injection schedules appear in most research discussions. The peptide does not meaningfully raise IGF-1, so it avoids the joint pain, fluid retention, and insulin resistance linked to hGH therapy.
AOD 9604 Peptide for Weight Loss: What the Research Shows
The human evidence behind aod 9604 peptide for weight loss is limited and mixed. An early phase II trial in obese adults reported greater weight loss than placebo, but a larger follow-up study failed to show a statistically significant difference between the peptide and the placebo group.
Commonly discussed peptide aod 9604 benefits include:
- Increased fat breakdown (lipolysis)
- Reduced fat storage (inhibited lipogenesis)
- Little to no effect on blood glucose in published trials
- No measurable rise in IGF-1
Those findings are interesting in theory but modest in practice. Anyone expecting prescription-drug levels of weight loss from AOD 9604 alone will likely be disappointed, because semaglutide and tirzepatide have far stronger clinical data behind them.
Dosage and Timing
There is no established human dose of AOD 9604, because the drug was never approved. Research and user reports commonly describe 250 mcg to 500 mcg per day injected subcutaneously, sometimes split into two smaller doses.
Questions about when to take aod 9604 peptide usually come down to timing around meals and training. Many protocols call for an injection on an empty stomach — often in the morning or before fasted cardio — based on the idea that insulin blunts lipolysis. That reasoning is plausible, but no controlled human trial has confirmed that timing changes the outcome.
| Protocol element | Common practice | Evidence level |
|---|---|---|
| Daily dose | 250–500 mcg | No established human dose |
| Injection site | Abdomen or thigh, subcutaneous | Standard peptide handling |
| Timing | Fasted, morning or pre-cardio | Theoretical, not proven |
| Cycle length | 8–12 weeks reported | Anecdotal only |
How AOD 9604 Compares to Tesamorelin and Retatrutide
| Peptide | Mechanism | FDA status | Typical research dose | Primary goal |
|---|---|---|---|---|
| AOD 9604 | hGH fragment 176–191; stimulates lipolysis, blocks lipogenesis | Not approved | 250–500 mcg daily, subQ | Fat loss without growth effects |
| Tesamorelin | GHRH analog; raises endogenous growth hormone | Approved (Egrifta) for HIV-associated lipodystrophy | 1–2 mg daily, subQ | Visceral fat reduction |
| Retatrutide | Triple agonist targeting GLP-1, GIP, and glucagon | Investigational, not approved | Trial doses up to 12 mg weekly | Large-scale weight loss |
When people search aod 9604 peptide vs tesamorelin, the practical difference is approval and evidence: tesamorelin is a prescribed medication with completed trials, while AOD 9604 remains an unapproved research peptide. Retatrutide sits in a completely different class, and its early trial results show weight loss in the double digits — a magnitude AOD 9604 has never demonstrated.
Legal Status, Sourcing, and Safety
AOD 9604 is not FDA-approved for human use. It also appears on the World Anti-Doping Agency prohibited list, so athletes subject to drug testing should avoid it. Vendors label it for research use only, and anyone looking to buy aod-9604 peptide online should assume the product is unregulated and its purity unverified.
Reported side effects are generally mild and include injection-site redness, swelling, and occasional headache or nausea. Long-term safety data in humans does not exist, and no one knows how the peptide interacts with most prescription medications.
Pregnant or breastfeeding women, people with thyroid or metabolic conditions, and anyone taking daily medication should speak with a licensed healthcare professional before injecting any peptide. Self-treating with unapproved substances carries real medical and legal risk.
The Bottom Line
AOD 9604 peptide injection is a research peptide with a plausible fat-burning mechanism, weak and inconsistent human trial results, and no regulatory approval. It is not a substitute for proven weight-loss treatment, structured nutrition, or medical care.
Frequently Asked Questions
Is AOD 9604 approved by the FDA?
No. AOD 9604 is not FDA-approved for human use in the United States and is legally sold only as a research chemical. It is also banned by the World Anti-Doping Agency, so tested athletes should avoid it. Any product marketed for human injection is unapproved and unregulated.
How much AOD 9604 do you inject?
There is no approved human dose. Research and user protocols commonly describe 250 mcg to 500 mcg per day injected subcutaneously, often on an empty stomach. Because the drug never completed approval trials, those numbers are not established medical guidance.
How long does AOD 9604 take to work?
Users typically report changes after 4 to 12 weeks of daily injections, if they notice anything at all. The peptide has a short half-life of roughly 30 minutes, which is why daily dosing is standard. No controlled human trial has confirmed a reliable timeline for fat loss.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.